Comparing Argon Plasma Device to Standard Surgery for Treating Ovarian Endometrioma in Women Aged 18 to 40

What this Trial Is About

Researchers are evaluating two surgical methods for treating ovarian endometrioma in women to understand how each method affects ovarian reserve. This pilot study compares the standard cystectomy procedure with argon plasma coagulation APC treatment by monitoring changes in serum Anti-Mller hormone AMH levels after surgery. The study is conducted as a prospective, randomized controlled trial at the Department for Womens Health in Tuebingen, Germany. Participants will be randomly assigned to one of two groups one receiving the standard cystectomy using lap bipolar forceps, and the other undergoing APC treatment with a CE-approved APC applicator device. The surgical treatment will be performed during the second visit. Follow-up visits are scheduled at three, six, and twelve months after the procedure, with AMH levels measured during the three- and six-month visits. The twelve-month follow-up will be conducted through a phone call. Women who qualify will participate in five visits screening, treatment, and three follow-ups. Screening occurs first to confirm eligibility. Blood tests to measure AMH levels will be done at the study site during follow-up visits three and four. The final follow-up will be remote via telemedicine. Safety and treatment effects will be assessed throughout, with the main outcome focused on changes in AMH concentration up to six months post-treatment.

Argon Plasma Treatment for Ovarian Endometrioma Compared to Standard Cystectomy